Tango Therapeutics (NASDAQ:TNGX) Announces Earnings Results, Beats Expectations By $0.02 EPS

Tango Therapeutics (NASDAQ:TNGX) issued its earnings results on Thursday. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.02, FiscalAI reports. Tango Therapeutics had a negative return on equity of 66.01% and a negative net margin of 151.15%.

Tango Therapeutics Price Performance

Shares of NASDAQ TNGX opened at $16.95 on Friday. The stock has a market capitalization of $2.28 billion, a price-to-earnings ratio of -19.48 and a beta of 1.76. Tango Therapeutics has a 12 month low of $1.03 and a 12 month high of $17.63. The firm’s 50 day simple moving average is $11.86 and its 200-day simple moving average is $9.44.

Tango Therapeutics News Summary

Here are the key news stories impacting Tango Therapeutics this week:

• Positive Sentiment: Clinical collaboration with Erasca to test ERAS‑0015/vopimetostat in MTAP‑deleted, RAS‑mutant cancers expands Tango’s clinical footprint and creates near‑term partnership newsflow that likely drove buying interest and record highs. TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS
• Positive Sentiment: HC Wainwright sharply raised its price target to $27 (buy), a large explicit upside that can boost sentiment and buy‑side conviction. HC Wainwright price target raise
• Positive Sentiment: Guggenheim raised its target to $20 and reiterated a buy rating, adding to analyst momentum and supporting the share‑price lift. Guggenheim price target raise
• Positive Sentiment: Wedbush raised its target to $19 with an “outperform” rating, another vote of confidence from sell‑side analysts that can attract new buyers. Wedbush price target raise
• Positive Sentiment: An investment firm added ~1.1M shares (~$9.5M), increasing its reported position materially — institutional buying that signals conviction and can underpin the rally. Investment Firm Bets Big on TNGX Stock
• Neutral Sentiment: Quarterly results beat EPS estimates by $0.02 (reported -$0.29 vs. -$0.31) — a modest positive but company remains unprofitable with negative margins and ROE, so financials are unlikely to change valuation narrative immediately. Tango Therapeutics press release
• Negative Sentiment: A Seeking Alpha piece warns against buying into the rally despite PRMT5 promise, highlighting clinical, competitive and valuation risks that could limit upside or prompt pullbacks if trial data or execution falter. Tango Therapeutics: I’m Not Buying Into Latest Rally

Analyst Ratings Changes

TNGX has been the subject of several research reports. Mizuho initiated coverage on shares of Tango Therapeutics in a research note on Monday, February 23rd. They set an “outperform” rating and a $19.00 price objective for the company. Wolfe Research started coverage on shares of Tango Therapeutics in a report on Tuesday, November 18th. They set a “peer perform” rating for the company. B. Riley Financial boosted their target price on shares of Tango Therapeutics from $8.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. Guggenheim upped their price target on shares of Tango Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a report on Friday. Finally, HC Wainwright increased their price target on Tango Therapeutics from $13.00 to $27.00 and gave the stock a “buy” rating in a research report on Friday. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.25.

Insider Activity at Tango Therapeutics

In related news, Director Barbara Weber sold 30,519 shares of the business’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $12.26, for a total value of $374,162.94. Following the completion of the transaction, the director directly owned 1,629,254 shares in the company, valued at $19,974,654.04. The trade was a 1.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Daniella Beckman sold 10,317 shares of the stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $12.26, for a total transaction of $126,486.42. Following the sale, the chief financial officer directly owned 184,297 shares in the company, valued at $2,259,481.22. This trade represents a 5.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 113,633 shares of company stock worth $1,420,857 in the last three months. Company insiders own 7.50% of the company’s stock.

Institutional Investors Weigh In On Tango Therapeutics

Several hedge funds have recently modified their holdings of TNGX. Bank of Montreal Can acquired a new position in Tango Therapeutics in the 4th quarter worth about $146,000. EverSource Wealth Advisors LLC grew its holdings in Tango Therapeutics by 102,326.9% in the second quarter. EverSource Wealth Advisors LLC now owns 26,631 shares of the company’s stock valued at $136,000 after purchasing an additional 26,605 shares during the period. BNP Paribas Financial Markets increased its position in shares of Tango Therapeutics by 75.3% in the third quarter. BNP Paribas Financial Markets now owns 15,090 shares of the company’s stock valued at $127,000 after buying an additional 6,481 shares in the last quarter. LPL Financial LLC purchased a new stake in shares of Tango Therapeutics in the fourth quarter valued at approximately $106,000. Finally, Invesco Ltd. lifted its position in shares of Tango Therapeutics by 138.8% during the 1st quarter. Invesco Ltd. now owns 70,517 shares of the company’s stock valued at $97,000 after buying an additional 40,983 shares in the last quarter. 78.99% of the stock is owned by hedge funds and other institutional investors.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.